Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) priced a public offering to raise approximately $48 million in gross proceeds, plus up to $168 million more if attached Class A and Class B warrants are fully exercised, potentially totaling $216 million. The offering includes double warrants exercisable at $24.12 (50% premium) and $32.16 (100% premium), each expiring in five years.
Company highlights IM8's rapid traction: $100M ARR in 11 months, October run-rate ~$103M ARR, and 2026 guidance $160–200M. Post-offering liquidity expected at ~$100M cash plus 275 BTC (~$31M), totaling ~$131M.
Prenetics (NASDAQ: PRE) priced a best-efforts public offering to sell 2,992,596 Class A ordinary shares (or pre-funded warrants) together with associated Class A and Class B common warrants at a combined offering price of $16.08 per unit, for expected gross proceeds of approximately $48.0 million before fees and expenses. The Class A warrants carry a $24.12 exercise price and Class B warrants a $32.16 exercise price; each warrant is immediately exercisable and expires five years after issuance.
Proceeds are intended to fund the global expansion of IM8 and the company’s strategic accumulation of Bitcoin (BTC). The offering is expected to close on October 28, 2025, subject to customary closing conditions, with Dominari Securities as placement agent.
Prenetics Global (NASDAQ:PRE) announced on Oct 25, 2025 that it has commenced a public offering of Class A ordinary shares (or prefunded warrants) and common warrants (the "Offering").
The company said net proceeds are intended to fund the global expansion of IM8 and the strategic accumulation of Bitcoin (BTC) as part of a dual health-and-wealth strategy. The Offering is being made from an effective Form F-3 shelf registration declared effective by the SEC on Sept 11, 2025, and is subject to market conditions with no assurance as to completion, size, or terms.
Dominari Securities is acting as sole placement agent; a preliminary prospectus supplement and shelf prospectus will be filed with the SEC and made available to investors.
Prenetics (NASDAQ: PRE) announced on October 8, 2025 the launch of Daily Ultimate Longevity under its IM8 brand. The powder formulation is described as the first supplement to target all 12 hallmarks of aging using a five-complex system with specified clinical ingredient doses (e.g., 3,000 mg glycine, 300 mg NMN, 3 mg spermidine).
IM8 reported rapid scaling from approximately $600k monthly at launch to $6.6M monthly revenue in September 2025 and cites a 2,457% CAGR, targeting $100M ARR within its first year. Product pricing is $149 one-time or $119/month subscription. Prenetics reports >$90M liquid assets (≈$60M cash and 255.4 BTC ≈$31.6M) and says it is debt-free with a path to profitability in early 2026.
Prenetics (NASDAQ: PRE) completed the divestment of ACT for $72 million, receiving $39.9 million in cash upfront and an additional $6.3 million held in escrow payable over 18 months, bringing total transaction proceeds to $46 million. The company says this lifts cash reserves to over $60 million (excluding Bitcoin) and leaves Prenetics debt-free. Prenetics is reallocating resources to its consumer health brand IM8, which is on pace to reach an $100 million ARR within its first 12 months. The company also reports a Bitcoin treasury of 255.4 BTC valued at $31.6 million (investment cost $27.8 million), an unrealized profit of $3.86 million (13.9% return), and a 1 BTC/day purchase policy since August 1, 2025.
Prenetics Global Limited (NASDAQ: PRE), a consumer health sciences company, announced CEO Danny Yeung will deliver a keynote at Token 2049 in Singapore on October 2, 2025. The presentation will focus on IM8, their supplement brand, and their Bitcoin treasury strategy.
The company currently holds 248.42 BTC at an average price of $108,600 per BTC, with a strategy to acquire 1 Bitcoin daily. Their supplement brand IM8 is projected to achieve $100 million in annual recurring revenue within its first year. Prenetics maintains a strong financial position with $63.5 million in current assets, including $46.3 million from ACT Genomics divestment, $17.2 million in cash, and other assets.
Prenetics (NASDAQ: PRE) reported strong Q2 2025 financial results, with revenue surging 594.9% YoY to $17.7 million. The company's flagship brand IM8 achieved $5.9 million in monthly revenue for August 2025, demonstrating a remarkable 3,100% CAGR since December 2024.
Key financial metrics include gross profit of $7.3 million (up 233.5% YoY) and adjusted EBITDA loss of $(4.1) million. The company maintains a strong balance sheet with $90.3 million in adjusted current assets, including $63.5 million cash. Notably, Prenetics has implemented a Bitcoin treasury strategy, accumulating 228.42 BTC valued at $26.1 million.
The company raised its FY2025 revenue guidance to $85-100 million and expects to achieve break-even by Q1 2026. IM8's strong performance is supported by partnerships with David Beckham and Aryna Sabalenka, with over 300,000 customer orders and 8 million product servings delivered to date.
Prenetics Global Limited (NASDAQ: PRE) celebrates as their global ambassador and shareholder, World No. 1 tennis player Aryna Sabalenka, successfully defends her US Open championship title. Sabalenka becomes the first woman since Serena Williams in 2014 to achieve this feat, marking her fourth Grand Slam victory.
The company's premium supplement brand IM8, co-founded by David Beckham, has shown remarkable growth since its December 2024 launch, with over 300,000 customer purchases and 6 million servings delivered. An AI-powered advertisement featuring Sabalenka has garnered 233 million Instagram views and is being displayed on Times Square billboards during the US Open.
IM8's Daily Ultimate Essentials, which is NSF Certified for Sport, combines 92 essential nutrients and replaces 16 individual supplements in a single drink format.
Prenetics Global Limited (NASDAQ: PRE) announced that world No. 1 tennis star Aryna Sabalenka has joined IM8 Health as both global ambassador and shareholder, marking the first time a current athlete has become a shareholder in Prenetics.
IM8, a premium supplements brand co-founded by David Beckham, has achieved remarkable growth since its December 2024 launch, generating over $50 million in Annual Recurring Revenue and serving 60,000+ customers with more than 5 million supplement servings. The company's NSF Certified for Sport® Daily Ultimate Essentials product has been part of Sabalenka's daily routine since early 2025, contributing to her successful season including titles in Brisbane, Miami, and Madrid.